linjc16/ctgov huggingface dataset:
Physical Therapy Rehabilitation Program Combined With Music on Pediatric With Lower Limb Burn

Study Overview
=================
Brief Summary
-----------------
The purpose of the current study was to evaluate the effect of physical therapy rehabilitation program combined with music therapy on pediatric with lower limb burn. Methods. A twelve-week randomized controlled study including thirty lower limb pediatric burned patients who randomly divided into two groups, Group(A) received physical therapy rehabilitation program combined with music therapy in addition to routine medical care while Group (B) received physical therapy rehabilitation program without music therapy. Pain was assessed by visual analogue scale (VAS) and range of motion (ROM) was assessed by goniometer, and gait assessed by GAIT Rite. Assessment was carried before and after treatment

Official Title
-----------------
Effect of Physical Therapy Rehabilitation Program Combined With Music on Pediatric With Lower Limb Burn: a Twelve-week Randomized Controlled Study

Conditions
-----------------
Lower Limb Burn

Intervention / Treatment
-----------------
* Other: Exercise with music


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Lower limb 2nd degree burn since 6 weeks Burn affect skin around ankle and knee joint, Both sex, age ranged between 10 to 15 years old Patients have sufficient cognition and education enough to understand the requirements of this study Exclusion Criteria: All patients with age more than 15 years or less than 10 years Patients with hearing problems Acute viral diseases, acute tuberculosis, mental disorders Those with pace makers, diabetics, cardiac, renal patients Patients with genetic disease 3rd degree burn and 1st degree bum

Ages Eligible for Study
-----------------
Minimum Age: 10 Years
Maximum Age: 15 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Exercise with music group<br>physical therapy program combined with music therapy | Other: Exercise with music<br>* physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.<br>|
| Experimental: Exercise group<br>physical therapy program without music | Other: Exercise with music<br>* physical therapy program combined with music therapy 15 min, 3 times weekly for 12 weeks.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| pain in the lower limb | Visual analogue scale for pain assessment ,zero indicates no pain ten indicates maximum pain | 12 weeks |
Dermatological Evaluation of Topical Compatibility, Primary Skin Irritability, Accumulated Skin Irritability, and Dermal Sensitisation

Study Overview
=================
Brief Summary
-----------------
Check the safety under normal conditions of use through the verification of emergence signs of irritability and sensitisation of the genital mucosa.

Official Title
-----------------
Dermatological Evaluation of Topical Compatibility, Primary Skin Irritability, Accumulated Skin Irritability, and Dermal Sensitisation

Conditions
-----------------
Skin Irritability

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Age between 18 to 70 years old; Skin types: I (light caucasian), II (caucasian), III (light dark) and IV (dark) intact skin where the product will be applied Agreement to comply with the test procedures and attend the clinic in the days and ixed times for medical assessments and application and reading of dressings Signature of informed consent form Exclusion Criteria: Pregnancy and lactation Use of anti-inflammatory and immunosuppressive drugs from 30 days up to three months prior to selection; Diseases that cause immune suppression; Personal history of atopy; History of sensitisation and irritability to topical products; Active cutaneous pathologies (local and / or scattered) that may interfere in the study results; Use of new drugs and/or cosmetics during the experiment; Skin reactivity; Previous participation in a study with the same product under test; Volunteers who have congenital or acquired known immunodeficiency; Relevant medical history or current evidence of alcohol or other drugs abuse; Known historical or suspected intolerance to any ingredient of the product under study (product under test or comparator); Sponsor's employees involved in the study, or close family member of an employee involved in the study;

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 70 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Evaluation of adverse effects in maximized conditions |  | 60 days |
Motivations for Weight Loss

Study Overview
=================
Brief Summary
-----------------
This study tests the effects of emphasizing different motivations for wanting to lose weight on weight loss maintenance in women. At the start of the study, participants will be weighed and will complete questionnaires about their health, weight history, eating and exercise habits, body satisfaction and mood. Participants will then be randomly assigned to 1 of 4 treatments. Participants in all 4 groups will receive information on topics related to eating and exercise, and will receive calorie and fat intake goals, and exercise goals. The 4 treatments will differ in the emphasis given to various reasons for wanting to lose weight. At 6, 12 and 18 months after enrollment, participants will again have weights measured and fill out questionnaires.

Official Title
-----------------
Weight Loss Motivations and Long-term Weight Loss

Conditions
-----------------
Obesity

Intervention / Treatment
-----------------
* Behavioral: Weight loss motivations


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Body mass index greater than or equal to 27 and less than or equal to 35 Rating both physical appearance and health concerns as important motivations for weight loss Successful completion of a food and exercise diary over a 5-day period

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 55 Years

Sexes Eligible for Study
-----------------
Female

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Intervention Model: Factorial Assignment


Arms and Interventions

| Intervention/Treatment |
| --- |
|Behavioral: Weight loss motivations|nan|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
overweight
Vitamin d Levels and Coronary Catheterization

Study Overview
=================
Brief Summary
-----------------
decreased vitamin d levels are associated with increased inflammatory markers,and renin angiotensin levels. decreased levels were also found to be connected to increased cardiovascular mortality. we therefore hypothesise that in patients with pathological results of coronary catheterization we will find decreased levels of 25 hydroxy vitamin d. we will examine patients undergoing elective coronary catheterization and compare two groups: those with normal results and those with pathological results.

Official Title
-----------------
25 Hydroxy Vitamin d Levels in Patients Undergoing an Elective Coronary Catheterization

Conditions
-----------------
Vitamin D Deficiency

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria:age >18 years, no known ihd Exclusion Criteria: renal failure , medications including vitamin d, calcium ,phosphate hyper or hypoparathyroidism, abnormal calcium or phosphate values, known pathological coronary catheterization.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| 1normal catheter.<br> | |
| abnormal catheter.<br> | |

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
vitamin d coronary catheterization
Evaluating the Treatment in the MZEB Aachen

Study Overview
=================
Brief Summary
-----------------
Evaluation of patient characteristics, involved physicians and therapists as well as therapies in a German University Center for the Treatment of patients with intellectual disabilities and severe multiple disability (MZEB Aachen)

Detailed Description
-----------------
In the MZEB Aachen, since 11/2018 patients with intellectual disabilities and/or severe multiple disabilities are diagnosed, treated and accompanied for many years in a multidisciplinary setting with physicians, nurses, physiotherapists, ergo therapists, speech therapists and Support by social workers. MZEBs are considered to have a pilot function in the health care system, cooperating with therapists and physicians in the surroundings. This concept is established as a new concept in Germany in order to optimise health care for patients with disabilities. Thus we want to investigate patient characteristics, diagnoses, involved physicians and therapists as well as proposed therapies and disease progress in this center.

Official Title
-----------------
Evaluating the Treatment in the the Center for Disabled People in Aachen (MZEB Aachen) - a Registry on Patients With Severe Disabilities

Conditions
-----------------
Intellectual Disability, Disability Physical

Intervention / Treatment
-----------------
* Other: standard treatment


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: intellectual disability and/or severe multiple disability (disability degree GdB at least 70 and at least one noticeable sign willing to participate Exclusion Criteria: housed in an Institution and/or prison

Ages Eligible for Study
-----------------
Minimum Age: 18 Years
Maximum Age: 80 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Other: standard treatment|there ist no Intervention but our standart Treatment in the center|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| change in number of therapy sessions | change in the number of therapy sessions per month | baseline and after one year treatment | 
| Change in diagnoses | Change in percentage of definite diagnoses | baseline and after one year treatment |
Ventilation Distribution During Spontaneous Breathing in Healthy Newborn Infants

Study Overview
=================
Brief Summary
-----------------
Electrical impedance tomography (EIT) is an evolving monitoring tool for respiratory support in neonatal and pediatric intensive care. In this observational study basic EIT parameters will be measured on 20 healthy newborn infants during spontaneous breathing and assess the effect of position changes in ventilation distribution.

Detailed Description
-----------------
NEO SensorBelts will be used to observe ventilation distribution in healthy newborn infants during quiet spontaneous breathing. Child's position will be changed 5 times every 10 minutes in a random order. Positions observed will be: left lateral, right lateral, supine, prone face to left, prone face to right and supine with the bed tilted 30 degrees. Total duration for the recording will be 1 hour.

Official Title
-----------------
Ventilation Distribution Observed With Electrical Impedance Tomography (EIT) During Spontaneous Breathing in Healthy Newborn Infants

Conditions
-----------------
Spontaneous Breathing, Full-Term Neonate

Intervention / Treatment
-----------------
* Device: Swisstom BB2 EIT device


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Written informed consent from a parent or legal guardian Gestational age 37+0 - 42+0 weeks Uneventful follow-up in maternity ward Exclusion Criteria: Respiratory distress Admission to NICU Thorax skin lesions Prior participation in this study

Ages Eligible for Study
-----------------
Minimum Age: 12 Hours
Maximum Age: 5 Days

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Intervention/Treatment |
| --- |
|Device: Swisstom BB2 EIT device|Swisstom BB2 EIT device with NEO SensorBelts will be used to measure ventilation distribution during spontaneous breathing and position changes in healthy newborn infants.|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Anteroposterior ventilation distribution | The ventral-to-dorsal center of ventilation will be calculated as described in (Frerichs et al., Acta AnaesthesiolScand. 1998; 42:721-726) as a value between 0 and 100%, higher values indicating a more dorsal distribution of ventilation. | 1 hour | 
| Right-to-left ventilation distribution | Changes in right-to-left ventilation distribution following position changes will be calculated | 1 hour |
Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients With Gastritis

Study Overview
=================
Brief Summary
-----------------
THe purpose of this study is to evaludate the Efficacy and Safety of DWC20155/DWC20156 Combination Therapy in Patients with Gastritis

Official Title
-----------------
A Multi-Center, Randomized, Parallel, Double-Blind, Phase III Clinical Trial to Compare the Efficacy and Safety of DWC20155/DWC20156 Combination Therapy With DWC20155 or DWC20156 Monotherapy in Patients With Gastritis

Conditions
-----------------
Gastritis

Intervention / Treatment
-----------------
* Drug: DWC20155
* Drug: DWC20156
* Drug: placebo of DWC20155
* Drug: placebo of DWC20156


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Male of female of at least 19 years old Patients diagnosed with acute or chronic gastritis by gastroscopy Patients with one or more erosions found by gastroscopy Exclusion Criteria: Patients with peptic ulcer and gastroesophageal reflux disease Patients with previous gastrointestinal surgery Patients with history of gastrointestinal cancer

Ages Eligible for Study
-----------------
Minimum Age: 19 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: DWC20155/DWC20156 Combination Therapy<br> | Drug: DWC20155<br>* tablet<br>Drug: DWC20156<br>* tablet<br>Drug: placebo of DWC20155<br>* tablet<br>|
| Active Comparator: DWC20155 Monotherapy<br> | Drug: DWC20155<br>* tablet<br>Drug: placebo of DWC20155<br>* tablet<br>Drug: placebo of DWC20156<br>* tablet<br>|
| Active Comparator: DWC20156 Monotherapy<br> | Drug: DWC20156<br>* tablet<br>Drug: placebo of DWC20155<br>* tablet<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Improvement rates of stomach erosions by the endoscopy |  | At 2 weeks |
Evaluation of Pain Regression in Patients With Myofascial Facial Pain Using Dextrose, Local Anaesthesia and Saline.

Study Overview
=================
Brief Summary
-----------------
The aim of this study is to compare the treatment effects of dextrose prolotherapy, saline, and mepivacaine for deactivating myofascial trigger points within the jaw muscles.

Official Title
-----------------
Evaluation of Pain Regression in Patients With Myofascial Facial Pain Treated by Dextrose Prolotherapy Versus Local Anesthetic Injections: A Prospective Double-blind Randomized Placebo-controlled Clinical Trial.

Conditions
-----------------
Myofascial Pain Syndrome

Intervention / Treatment
-----------------
* Other: Dextrose Prolotherapy
* Other: Local Anaesthesia
* Other: Saline


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: - 1. Presence of active myofacial pains in jaw muscles, previously identified by manual palpation. 2. Age ≥ 18 years. 3. Willingness to follow instructions Exclusion Criteria: 1. Therapeutic intervention for myofascial pain within the past month before the study, such as using of medications for pain control or wearing of occlusal splint. 2. Clinical conditions such as pregnancy. 3. Medical problems that may interfere with the procedures such as bleeding disorders, trigeminal neuralgia. 4. Recent facial or neck trauma; medication or adjunctive treatment (eg, physiotherapy) that could not be stopped during the study; or allergy to local anesthetic solutions. 5. Cognitive impairment or exhibited inadequate cooperation.

Ages Eligible for Study
-----------------
Minimum Age: 18 Years

Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
Accepts Healthy Volunteers

Study Plan
=================
How is the study designed?
-----------------

Design Details

Primary Purpose: Treatment
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Single


Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Experimental: Dextrose Prolotherapy<br> | Other: Dextrose Prolotherapy<br>* Dextrose is a solution, mixture of dextrose and water.<br>|
| Active Comparator: Local Anaesthetic<br> | Other: Local Anaesthesia<br>* A local anaesthetic is a medication that causes reversible absence of pain sensation<br>|
| Placebo Comparator: Saline<br> | Other: Saline<br>* Saline is a control group<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Patients' subjective pain experience | Pressure pain threshold (PPT): An algometer will be used to assess PPT. The algometer consists of a 1 cm2 rubber tipped plunger mounted on a force transducer. The pressure will be applied over the examined trigger point. The participants will be instructed to point when the sensation changed from pressure to pain. The mean of three trials will be calculated and used for analysis. | one year |
Fosrenol Post-marketing Surveillance for Hemodialysis in Japan

Study Overview
=================
Brief Summary
-----------------
This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in hemodialysis who received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. A total 3,000 patients will be recruited and followed 5 years.

Official Title
-----------------
Special Drug Use Investigation of Fosrenol (Long-term Investigation for Patients With Hemodialysis)

Conditions
-----------------
Hyperphosphatemia

Intervention / Treatment
-----------------
* Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet


Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Patients undergoing hemodialysis who received Fosrenol for hyperphosphatemia Exclusion Criteria: Patients who are contraindicated based on the product label
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------

Arms and Interventions

| Participant Group/Arm | Intervention/Treatment |
| --- | --- |
| Group 1<br>Drug (incl. Placebo) | Drug: Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet<br>* Patients in hemodialysis who have received Fosrenol for hyperphosphatemia.<br>|

What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Incidence of adverse drug reactions in subjects who received Fosrenol |  | After Fosrenol administration, up to 8 years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Timing of onset of common ADRs related to the priority survey items | The items are Gastrointestinal symptoms Secondary hyperparathyroidism Hypocalcaemia and decreased blood calcium | After Fosrenol administration, up to 8 years | 
| Effect on bones: Alkaline phosphatase over time |  | After Fosrenol administration, up to 8 years | 
| Effect on bones: Change in bone density |  | After Fosrenol administration, up to 8 years | 
| Cardiothoracic ratio over time |  | After Fosrenol administration, up to 8 years | 
| PWV and ABI over time |  | After Fosrenol administration, up to 8 years | 
| Serum P, albumin-corrected serum Ca and serum intact PTH, and Ca-P product over time |  | After Fosrenol administration, up to 8 years | 
| Percentage of patients achieving the serum P control goal |  | After Fosrenol administration, up to 8 years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Fosrenol, Hyperphosphatemia, Hemodialysis